ES2569240T3 - Polipéptidos y anticuerpos obtenidos a partir de células de leucemia linfocítica crónica y usos de los mismos - Google Patents

Polipéptidos y anticuerpos obtenidos a partir de células de leucemia linfocítica crónica y usos de los mismos Download PDF

Info

Publication number
ES2569240T3
ES2569240T3 ES11009020.6T ES11009020T ES2569240T3 ES 2569240 T3 ES2569240 T3 ES 2569240T3 ES 11009020 T ES11009020 T ES 11009020T ES 2569240 T3 ES2569240 T3 ES 2569240T3
Authority
ES
Spain
Prior art keywords
antibodies
polypeptides
cells
seq
sequence indicated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES11009020.6T
Other languages
English (en)
Spanish (es)
Inventor
Katherine S. Bowdish
John Mcwhirter
Anke Kretz-Rommel
Toshiaki Maruyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/894,672 external-priority patent/US9249229B2/en
Priority claimed from US10/996,316 external-priority patent/US7408041B2/en
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2569240T3 publication Critical patent/ES2569240T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ES11009020.6T 2004-07-20 2005-07-19 Polipéptidos y anticuerpos obtenidos a partir de células de leucemia linfocítica crónica y usos de los mismos Expired - Lifetime ES2569240T3 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US10/894,672 US9249229B2 (en) 2000-12-08 2004-07-20 Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US894672 2004-07-20
US996316 2004-11-23
US10/996,316 US7408041B2 (en) 2000-12-08 2004-11-23 Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US11/171,567 US20060057651A1 (en) 2000-12-08 2005-06-30 Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US171567 2005-06-30

Publications (1)

Publication Number Publication Date
ES2569240T3 true ES2569240T3 (es) 2016-05-09

Family

ID=35907987

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11009020.6T Expired - Lifetime ES2569240T3 (es) 2004-07-20 2005-07-19 Polipéptidos y anticuerpos obtenidos a partir de células de leucemia linfocítica crónica y usos de los mismos

Country Status (8)

Country Link
US (4) US20060057651A1 (enExample)
EP (2) EP1786464A4 (enExample)
JP (2) JP2008513354A (enExample)
AU (1) AU2005274785B2 (enExample)
CA (1) CA2574488C (enExample)
DK (1) DK2441777T3 (enExample)
ES (1) ES2569240T3 (enExample)
WO (1) WO2006020266A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7408041B2 (en) * 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
JP2010515751A (ja) * 2007-01-11 2010-05-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄ２００およびそのレセプターｃｄ２００ｒは破骨細胞の分化を介して骨質量を調節する
SI3187506T1 (sl) * 2007-05-21 2019-08-30 Alderbio Holdings Llc Protitelesa proti IL-6 in njihova uporaba
WO2009005673A1 (en) * 2007-06-28 2009-01-08 Schering Corporation Anti-igf1r
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
AU2016228280B2 (en) * 2007-07-12 2019-02-21 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
KR20100041849A (ko) * 2007-07-25 2010-04-22 알렉시온 파마슈티칼스, 인코포레이티드 Ｃｄ200에 대한 항체와 면역 반응의 저해에서 이들의 용도
JP2011516840A (ja) * 2008-04-04 2011-05-26 トリリウム セラピューティクス インコーポレーティッド 可溶性ｃｄ２００に関するアッセイ法
DE102008023820A1 (de) * 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
EP2373690B1 (en) 2008-12-08 2015-02-11 Compugen Ltd. Antibodies specific for tmem154
TWI729512B (zh) 2008-12-09 2021-06-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
US9180186B2 (en) * 2010-01-11 2015-11-10 Alexion Pharmaceuticals, Inc. Biomarkers of immunomodulatory effects in humans treated with anti-CD200 antibodies
RU2012138703A (ru) * 2010-02-11 2014-03-20 Алексион Фармасьютикалз, Инк. Терапевтические и диагностические способы с применением анти-cd200 антител
WO2012035518A1 (en) 2010-09-17 2012-03-22 Compugen Ltd. Compositions and methods for treatment of drug resistant multiple myeloma
AU2012212066A1 (en) 2011-02-03 2013-08-15 Alexion Pharmaceuticals, Inc. Use of an anti-CD200 antibody for prolonging the survival of allografts
KR20120093002A (ko) * 2011-02-14 2012-08-22 (주)에이티젠 Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트
ES2685821T3 (es) 2011-06-10 2018-10-11 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of National Defence Anticuerpos anti-ricina y sus usos
EP2723380B1 (en) 2011-06-24 2019-08-21 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
WO2013052432A1 (en) 2011-10-05 2013-04-11 Dharmacon, Inc. Optimization of vectors for effective delivery and expression of genetic content
CN112587658A (zh) * 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
US10548985B2 (en) 2014-01-10 2020-02-04 Birdie Biopharmaceuticals, Inc. Compounds and compositions for treating EGFR expressing tumors
CA2954446A1 (en) 2014-07-09 2016-01-14 Shanghai Birdie Biotech, Inc. Anti-pd-l1 combinations for treating tumors
CN112546238A (zh) 2014-09-01 2021-03-26 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
CN112972492B (zh) * 2015-12-16 2024-11-08 沃尔特及伊莱萨霍尔医学研究院 Nk细胞中对细胞因子诱导的sh2蛋白的抑制
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合
CN115350279A (zh) 2016-01-07 2022-11-18 博笛生物科技有限公司 用于治疗肿瘤的抗-her2组合
CN115252792A (zh) 2016-01-07 2022-11-01 博笛生物科技有限公司 用于治疗肿瘤的抗-egfr组合
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
US20190048055A1 (en) * 2017-03-31 2019-02-14 Altor Bioscience Corporation Alt-803 in combination with anti-cd38 antibody for cancer therapies
CN108794467A (zh) 2017-04-27 2018-11-13 博笛生物科技有限公司 2-氨基-喹啉衍生物
CA3067268A1 (en) 2017-06-23 2018-12-27 Birdie Biopharmaceuticals, Inc. Crystalline resiquimod monosulfate anhydrate and its preparation and uses
WO2019067499A1 (en) 2017-09-27 2019-04-04 Alexion Pharmaceuticals, Inc. BIOMARKER SIGNATURE FOR PREDICTING A TUMOR RESPONSE TO ANTI-CD200 THERAPY
WO2019126133A1 (en) 2017-12-20 2019-06-27 Alexion Pharmaceuticals, Inc. Liquid formulations of anti-cd200 antibodies
US11802154B2 (en) 2017-12-20 2023-10-31 Alexion Pharmaceuticals, Inc. Humanized anti-CD200 antibodies and uses thereof
CN109239334A (zh) * 2018-09-10 2019-01-18 吉林大学 建立时间分辨荧光免疫层析法检测MxA试剂盒
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN109633142B (zh) * 2018-12-22 2021-08-27 中国人民解放军第四军医大学 一种急性髓细胞性白血病诊断模型的建立方法及其应用

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US4289747A (en) 1978-12-26 1981-09-15 E-Y Laboratories, Inc. Immunological determination using lectin
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
DE3307869A1 (de) 1983-03-05 1984-09-06 Dragoco Gerberding & Co Gmbh, 3450 Holzminden Methylsubstituierte 1-((3-methylthio)-1-oxo-butyl)-cyclohex-2-ene, verfahren zu deren herstellung und deren verwendung als riech- und aromastoffe
EP0170697B1 (en) 1984-02-08 1991-10-23 Cetus Oncology Corporation Toxin conjugates
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1988006630A1 (en) 1987-03-02 1988-09-07 Genex Corporation Method for the preparation of binding molecules
JPH0246297A (ja) * 1988-08-08 1990-02-15 Takeda Chem Ind Ltd モノクローナル抗体、抗体産生ハイブリドーマおよび抗体の製造法
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5780279A (en) 1990-12-03 1998-07-14 Genentech, Inc. Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
ES2287206T3 (es) 1991-03-01 2007-12-16 Dyax Corporation Proceso para el desarrollo de mini-proteinas de union.
KR100238712B1 (ko) * 1991-06-27 2000-01-15 스티븐 비. 데이비스 씨티엘에이4 수용체,그를 함유한 연합단백질 및 그의 용도
US5728815A (en) 1992-03-30 1998-03-17 Board Of Regents, The University Of Texas System Bone and prostate-derived protein factors affecting prostate cancer growth, differentiation, and metastasis
US5508717A (en) 1992-07-28 1996-04-16 Sony Corporation Computer pointing device with dynamic sensitivity
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
EP0858506A4 (en) * 1995-10-31 2004-12-08 Uab Research Foundation GENETIC INDUCTION OF RECEPTORS TO TARGETED RADIOTHERAPY
AU1144097A (en) 1995-12-08 1997-07-03 Brigham And Women's Hospital Ox-2 costimulatory molecule
IL125928A (en) * 1996-03-20 2002-11-10 Bristol Myers Squibb Co The use of soluble ligands that react with CTLA4, B7, CD40, gp39 and / or CD28 for the preparation of pharmaceutical preparations
US6011138A (en) * 1997-02-20 2000-01-04 Idec Pharmaceuticals Corporation Gamma-1 anti-human CD23 monoclonal antibodies
US7223729B2 (en) * 1997-11-07 2007-05-29 Trillium Therapeutics Inc. Methods of treating allergy by administering a CD200 protein
JP4584447B2 (ja) * 1997-11-07 2010-11-24 トリリアム・セラピューティクス・インコーポレイテッド 免疫調節のための方法および組成物
US6955811B2 (en) * 1997-11-07 2005-10-18 Trillium Therapeutics Inc. Methods of inhibiting immune response suppression by administering antibodies to OX-2
DE19829473C2 (de) * 1998-07-01 2000-08-10 Magnus Von Knebel Doeberitz Ch Verfahren zur frühen Diagnose von Carcinomen
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US20020192215A1 (en) * 1999-04-13 2002-12-19 Schering Corporation, A New Jersey Corporation Novel uses of mammalian OX2 protein and related reagents
AU2001242159B2 (en) * 2000-03-17 2006-04-27 Trillium Therapeutics Inc. Methods and compositions for immunoregulation
US7306801B2 (en) * 2000-05-15 2007-12-11 Health Research, Inc. Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
WO2002011762A2 (en) * 2000-08-03 2002-02-14 Gorczynski Reginald M Methods and compositions for modulating tumor growth
US20030017491A1 (en) * 2000-09-14 2003-01-23 Zuo-Rong Shi Chromogenic in situ hybridization methods, kits, and compositions
DE60135573D1 (de) * 2000-11-22 2008-10-09 Trillium Therapeutics Inc Verkürztes cd200
EP1355942B1 (en) 2000-12-07 2008-08-27 Eli Lilly And Company Glp-1 fusion proteins
CA2436595C (en) * 2000-12-08 2011-11-08 Alexion Pharmaceuticals, Inc. Chronic lymphocytic leukemia cell line and its use for producing an antibody
AU2004217434B2 (en) * 2000-12-08 2010-08-26 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20040198661A1 (en) * 2000-12-08 2004-10-07 Bowdish Katherine S. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US7408041B2 (en) * 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US7368535B2 (en) 2001-05-24 2008-05-06 Trillium Therapeutics Inc. CD200 receptors
DE60234369D1 (de) 2001-09-19 2009-12-24 Alexion Pharma Inc Manipulierte matrizen und ihre verwendung bei der single-primer-amplifikation
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
EP1585545A4 (en) 2002-12-27 2006-04-12 Schering Corp PROCESS FOR INDUCING AND MAINTAINING IMMUNE COMPATIBILITY
JP2006520610A (ja) 2003-03-04 2006-09-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド ハイブリッド不変領域を産生するのに用いるベクター
EP1635872A4 (en) 2003-05-30 2008-01-02 Alexion Pharma Inc ANTIBODIES AND FUSION PROTEINS COMPRISING MODIFIED CONSTANT REGIONS
US6953417B2 (en) * 2003-11-17 2005-10-11 Borgwarner Inc. Method for controlling a dual clutch transmission
US20050169870A1 (en) * 2004-02-02 2005-08-04 Schering Corporation Methods of modulating CD200
EP1756165A2 (en) * 2004-06-02 2007-02-28 Sidney Kimmel Cancer Center Tissue-specific imaging and therapeutical agents targeting proteins expressed on lung endothelial cell surface
EP2325206B1 (en) 2004-11-12 2014-03-19 Xencor, Inc. Fc variants with altered binding to fcrn
BRPI0612814A2 (pt) * 2005-07-11 2017-06-20 Macrogenics Inc anticorpo, métodos para redução e para tratamento de uma resposta imune prejudicial em um mamífero, proteína de ligação ao cd16a, e, método para redução dos efeitos colaterais de primeira dose em um paciente
DK1931709T3 (en) * 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
EP1984403A2 (en) 2006-01-12 2008-10-29 Alexion Pharmaceuticals, Inc. Antibodies to ox-2/cd200 and uses thereof
US20080131428A1 (en) * 2006-02-24 2008-06-05 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2

Also Published As

Publication number Publication date
AU2005274785B2 (en) 2012-05-03
EP2441777A3 (en) 2012-07-25
AU2005274785A1 (en) 2006-02-23
JP2012111780A (ja) 2012-06-14
JP2008513354A (ja) 2008-05-01
EP2441777B1 (en) 2016-02-17
JP5727406B2 (ja) 2015-06-03
WO2006020266A3 (en) 2009-03-12
US7915000B2 (en) 2011-03-29
US8999328B2 (en) 2015-04-07
CA2574488A1 (en) 2006-02-23
WO2006020266A2 (en) 2006-02-23
EP1786464A4 (en) 2009-09-02
US20150368341A1 (en) 2015-12-24
EP1786464A2 (en) 2007-05-23
DK2441777T3 (en) 2016-05-17
US20090074759A1 (en) 2009-03-19
US20110236387A1 (en) 2011-09-29
EP2441777A2 (en) 2012-04-18
US20060057651A1 (en) 2006-03-16
CA2574488C (en) 2016-11-15

Similar Documents

Publication Publication Date Title
ES2569240T3 (es) Polipéptidos y anticuerpos obtenidos a partir de células de leucemia linfocítica crónica y usos de los mismos
Hodgins et al. Killers 2.0: NK cell therapies at the forefront of cancer control
KR102875950B1 (ko) 이중특이적 항-psma x 항-cd28 항체 및 이의 용도
ES3003809T3 (en) Chimeric antigen receptors specific for b-cell maturation antigen and encoding polynucleotides
ES2649155T3 (es) Anticuerpos anti-OX40 y procedimientos de uso de los mismos
JP2022515611A (ja) 二重特異性抗ｍｕｃ１６×抗ｃｄ２８抗体およびその使用
JP7635401B2 (ja) 抗ｔｎｆｒ２ヒト化抗体及びその使用
UA126441C2 (uk) Химерні антигенні рецептори, націлені на bcma, та способи їх застосування
JP2020528744A (ja) がん細胞を標的化するキメラ抗原受容体のための方法および組成物
JP2020526194A (ja) 免疫療法薬と関連する毒性を評価するためのマウスモデル
JP2015534819A5 (enExample)
JP2020502147A (ja) 制御性ｂ１０細胞を枯渇させる抗体および方法並びに免疫チェックポイント阻害剤との併用における使用
RU2012134369A (ru) Биомаркеры иммуномодулирующих эффектов у людей, подвергнутых лечению антиметаллами против cd200
AU2017206618A1 (en) Combination therapy comprising a superagonistic antibody against interleukin-2 and a checkpoint blockade agent
CN111388664A (zh) 干细胞增强疗法
Song et al. Eomesodermin is required for antitumor immunity mediated by 4-1BB-agonist immunotherapy
CN108699152A (zh) 嵌合犬抗cd20抗体
Roe et al. Targeting antigens to CD180 but not CD40 programs immature and mature B cell subsets to become efficient APCs
CA3082818A1 (en) Methods for selective expansion of .delta.3 .gamma..delta. t-cell populations and compositions thereof
US20240059787A1 (en) HERV-K Antibody Therapeutics
Steinbach et al. Clinical application of dendritic cells and interleukin-2 and tools to study activated T cells in horses—First results and implications for quality control
JP2024015377A (ja) 複合状態を有する細胞混合物を用いた、免疫寛容を誘導する抗体、及び誘導されたリンパ球、また誘導されたリンパ球を用いる細胞治療剤及び治療法
JP5626990B2 (ja) Ｔｈ２細胞誘導用組成物およびＴｈ２型疾患の治療組成物、ならびにこれらの利用
US20240190965A1 (en) Targeting anti-human pd 1h/vista to treat hematologic disorders
Wierz Characterization of the Tumor Microenvironment in Chronic Lymphocytic Leukemia by Mass Cytometry: Implications for Immunotherapy